FLT3 and acute myeloid leukemia: Among these, midostaurin (an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor) and enasidenib (an oral Isocitrate dehydrogenase 2 (IDH-2) inhibitor) are directed on two mutations detected in a significant amount of AML patients.